W
William C. Hahn
Researcher at Harvard University
Publications - 515
Citations - 85047
William C. Hahn is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 130, co-authored 448 publications receiving 72191 citations. Previous affiliations of William C. Hahn include Brigham and Women's Hospital & University of Washington.
Papers
More filters
Journal ArticleDOI
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Steffen Boettcher,Steffen Boettcher,Steffen Boettcher,Peter Miller,Peter Miller,Peter Miller,Rohan Sharma,Rohan Sharma,Marie McConkey,Marie McConkey,Matthew Leventhal,Matthew Leventhal,Andrei V. Krivtsov,Andrew O. Giacomelli,Andrew O. Giacomelli,Andrew O. Giacomelli,Waihay Wong,Waihay Wong,Jesi Kim,Sherry Chao,Sherry Chao,Kari J. Kurppa,Xiaoping Yang,Kirsten Milenkowic,Federica Piccioni,David E. Root,Frank G. Rücker,Yael Flamand,Donna Neuberg,R. Coleman Lindsley,R. Coleman Lindsley,Pasi A. Jänne,William C. Hahn,William C. Hahn,Tyler Jacks,Hartmut Döhner,Scott A. Armstrong,Benjamin L. Ebert +37 more
TL;DR: A study of leukemia refutes the hypothesis that p53 missense mutations confer new oncogenic functions to the p53 protein, and demonstrates that missense variants in the DNA-binding domain exert a dominant-negative effect (DNE) that confers a selective advantage to hematopoietic cells on DNA damage.
Journal ArticleDOI
Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell Transformation
Jessica E. Hutti,Rhine R. Shen,Rhine R. Shen,Derek W. Abbott,Alicia Y. Zhou,Alicia Y. Zhou,Kam Sprott,John M. Asara,John M. Asara,William C. Hahn,William C. Hahn,Lewis C. Cantley,Lewis C. Cantley,Lewis C. Cantley +13 more
TL;DR: IKKepsilon and CYLD are defined as an oncogene-tumor suppressor network that participates in tumorigenesis and phosphorylation of CYLD at serine 418 decreases its deubiquitinase activity and is necessary for IKKep silon-driven transformation.
Journal ArticleDOI
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre,Jonathan A. Nowak,Jonathan A. Nowak,Nicholas D. Camarda,Richard A. Moffitt,Arezou A. Ghazani,Arezou A. Ghazani,Arezou A. Ghazani,Mehlika Hazar-Rethinam,Srivatsan Raghavan,Jaegil Kim,Lauren K. Brais,Dorisanne Y. Ragon,Marisa W. Welch,Emma Reilly,Devin McCabe,Lori Marini,Lori Marini,Kristin Anderka,Karla Helvie,Karla Helvie,Nelly Oliver,Nelly Oliver,Ana Babic,Annacarolina da Silva,Annacarolina da Silva,Brandon Nadres,Emily E. Van Seventer,Heather A. Shahzade,Joseph P. St. Pierre,Kelly P. Burke,Kelly P. Burke,Thomas E. Clancy,Thomas E. Clancy,James M. Cleary,James M. Cleary,Leona A. Doyle,Leona A. Doyle,Kunal Jajoo,Kunal Jajoo,Nadine Jackson McCleary,Nadine Jackson McCleary,Jeffrey A. Meyerhardt,Jeffrey A. Meyerhardt,Janet E. Murphy,Kimmie Ng,Kimmie Ng,Anuj K. Patel,Anuj K. Patel,Kimberly Perez,Kimberly Perez,Michael H. Rosenthal,Michael H. Rosenthal,Douglas A. Rubinson,Douglas A. Rubinson,Marvin Ryou,Marvin Ryou,Geoffrey I. Shapiro,Geoffrey I. Shapiro,Ewa Sicinska,Stuart G. Silverman,Stuart G. Silverman,Rebecca J. Nagy,Richard B. Lanman,Deborah Knoerzer,Dean Welsch,Matthew B. Yurgelun,Matthew B. Yurgelun,Charles S. Fuchs,Levi A. Garraway,Gad Getz,Gad Getz,Jason L. Hornick,Jason L. Hornick,Bruce E. Johnson,Matthew H. Kulke,Matthew H. Kulke,Robert J. Mayer,Robert J. Mayer,Jeffrey W. Miller,Paul B. Shyn,Paul B. Shyn,David A. Tuveson,Nikhil Wagle,Jen Jen Yeh,William C. Hahn,Ryan B. Corcoran,Scott L. Carter,Brian M. Wolpin,Brian M. Wolpin +89 more
TL;DR: Using an integrated multidisciplinary biopsy program, it is demonstrated that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease.
Journal ArticleDOI
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal,Lei Shi,Leah Y. Liu,Ferran Fece de la Cruz,Jochen K. Lennerz,Srivatsan Raghavan,Srivatsan Raghavan,Ignaty Leschiner,Liudmila Elagina,Giulia Siravegna,Raymond W.S. Ng,Raymond W.S. Ng,Phuong Vu,Krushna C. Patra,Supriya K. Saha,Raul N. Uppot,Ronald S. Arellano,Stephanie Reyes,Takeshi Sagara,Sachie Otsuki,Brandon Nadres,Heather A. Shahzade,Ipsita Dey-Guha,Isobel J Fetter,Islam Baiev,Emily E. Van Seventer,Janet E. Murphy,Cristina R. Ferrone,Kenneth K. Tanabe,Vikram Deshpande,James J. Harding,Rona Yaeger,Robin Kate Kelley,Alberto Bardelli,A. John Iafrate,William C. Hahn,William C. Hahn,Cyril H. Benes,David T. Ting,Hiroshi Hirai,Gad Getz,Gad Getz,Dejan Juric,Andrew X. Zhu,Ryan B. Corcoran,Nabeel Bardeesy +45 more
TL;DR: It is reported that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347 and suggests that strategic sequencing of FGFR inhibitors, guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition in patients withFGFR2 fusion- positive ICC.
Journal ArticleDOI
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
Qing Sheng,Xinggang Liu,Eleanor Fleming,Karen Yuan,Huiying Piao,Huiying Piao,Jinyun Chen,Zeinab Moustafa,Roman K. Thomas,Heidi Greulich,Anna C. Schinzel,Anna C. Schinzel,Sara Zaghlul,David Bryant Batt,Seth Ettenberg,Matthew Meyerson,Matthew Meyerson,Birgit Schoeberl,Andrew L. Kung,William C. Hahn,William C. Hahn,Ronny Drapkin,Ronny Drapkin,David M. Livingston,Joyce F. Liu +24 more
TL;DR: Perturbation of this circuit with ErbB3-directed RNAi decreased cell growth in three-dimensional culture and resulted in decreased disease progression and prolonged survival in a xenograft mouse model of ovarian cancer.